(Q36642170)

English

A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer

scientific article published on August 2000

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Kollmannsberger C

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Quietzsch D

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Haag C

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Lingenfelser T

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Schroeder M

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Hartmann JT

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Baronius W

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Hempel V

8

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Clemens M

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Kanz L

10

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Bokemeyer C

11

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

1 August 2000

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

83

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

458-462

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

30 September 2017

Phase II study of paclitaxel in pretreated advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

30 September 2017

Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

30 September 2017

A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

30 September 2017

A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

30 September 2017

Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

30 September 2017

The treatment of advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

30 September 2017

Chemotherapy of carcinoma of the stomach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

30 September 2017

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

30 September 2017

Reporting results of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

30 September 2017

Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

30 September 2017

Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

30 September 2017

Taxol: a novel investigational antimicrotubule agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

30 September 2017

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

30 September 2017

cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

30 September 2017

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

28 June 2018

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

28 June 2018

Paclitaxel-induced apoptosis in human gastric carcinoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

28 June 2018

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

20 September 2018

Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374647

20 September 2018

Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell Lines in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/10945491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy of gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10945491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10945491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10945491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy for Advanced Gastric Cancer: Focus on New Agents and Combinations

1 reference

https://pubmed.ncbi.nlm.nih.gov/10945491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10945491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cisplatin plus continuous infusion of 5-fluorouracil for 5 days effective for patients with advanced gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10945491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus

1 reference

https://pubmed.ncbi.nlm.nih.gov/10945491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/10945491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer--a phase II study in elderly patients or patients with cardiac risk

1 reference

https://pubmed.ncbi.nlm.nih.gov/10945491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/10945491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of Taxol in patients with advanced gastric carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/10945491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1054/BJOC.2000.1295

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36642170&oldid=2199130124"